Not all clients with CLL require therapy. Even with all recent improvements, the iwCLL continue to recommends watchful observation for sufferers with asymptomatic sickness.86 This recommendation relies on no less than two randomized trials comparing observation to either chlorambucil monotherapy or fludarabine, cyclophosphamide and rituximab (FCR).